Latest Healthcare News

Vectus Biosystems has agreed to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics for US$3 million in shares and warrants, gaining a strategic equity position while refocusing on its cardiovascular and fibrosis pipeline.

Zoono Group Limited has responded to an ASX price query following a recent surge in its share price and trading volume, confirming no undisclosed information exists and attributing market activity to ongoing shelf-life extension trials across multiple continents.

Vectus Biosystems has requested an immediate suspension of its ASX-listed shares pending a significant announcement about a transaction involving a compound in its drug library.

Orthocell has raised $30 million through an institutional placement to accelerate the US commercialisation of its flagship nerve repair product Remplir and expand its regenerative medicine portfolio.

AVITA Medical has appointed Board Chairman Cary Vance as Interim CEO following Jim Corbett's departure, while preliminary third-quarter revenue is expected to reach approximately $17 million.

INOVIQ Limited has completed a $9.5 million placement to institutional investors and launched a $2 million Share Purchase Plan for existing shareholders, aiming to bolster its cancer diagnostics and therapeutics pipeline.

PainChek Limited has appointed Sasha Grant as Head of Growth for its AI-powered Infant App, aiming to scale its presence in a $15 billion global market. Early Australian adoption shows promising conversion rates as the company prepares for international expansion.

Biome Australia Limited has reported a record quarterly revenue of $5.94 million for Q1 FY26, marking a 40% increase year-over-year and its seventh consecutive quarter of positive EBITDA. The company’s strong cash flow and sustained margins underscore its growth momentum.

Alcidion Group Limited has reported a record FY25 with strong revenue growth, major NHS contract wins, and expanded AI capabilities in its Miya Precision platform, setting the stage for global healthcare IT expansion.

PainChek Limited has confirmed FDA De Novo classification for its PainChek Adult App, promptly disclosing the material regulatory milestone to the ASX and signalling a significant step towards US market entry.

Health Canada has requested additional information, extending its review of CLINUVEL’s SCENESSE® for erythropoietic protoporphyria (EPP) into 2026. Meanwhile, Canadian patients continue to access the treatment via a Special Access Program.

PolyNovo Limited has appointed Bruce Peatey as its new CEO, bringing extensive international healthcare experience to drive the company’s next growth phase. Peatey’s leadership is expected to accelerate PolyNovo’s expansion into new markets and outpatient care.